HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. TECENTRIQ (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2024 RECENT MAJOR CHANGES
atezolizumab (Tecentriq, Genetech, Inc). These include non-small Important prescribing information is listed for arimoclomol. Most
FDA granted accelerated approval to Tecentriq (atezolizumab) for FDA approved an expansion to the Imbruvica (ibrutinib) prescribing information
intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc Full prescribing information for Tecentriq Hybreza will be posted on Drugs
Tecentriq (Atezolizumab). The purpose of this form is to obtain Have the prescribing physician complete the Physician Information sections.
See 17 for PATIENT COUNSELING INFORMATION and Medication HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. TECENTRIQ (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2024
Recommendations from the TECENTRIQ (atezolizumab) Prescribing Information 1. No dose reduction for TECENTRIQ is recommended. In general, withhold TECENTRIQ for severe (grade 3) immune-mediated ARs.
Tecentriq / Tecentriq Hybreza Venclexta Find product and prescribing information, as well as other resources, for Genentech's oncology portfolio below.
TECENTRIQ can cause fetal harm in pregnant women. Please see accompanying full Prescribing Information for additional Important Safety Information.
Comments